Enrique Grande

Enrique Grande: Intravesical durvalumab shows promise for high-risk NMIBC after BCG failure

Enrique Grande, Head of Oncology at MD Anderson Cancer Center, shared a post on LinkedIn about a recent paper by Charalampos Fragkoulis et al. published in European Urology:

“Intravesical durvalumab (1000 mg every 6 weeks) shows promise for high-risk NMIBC after BCG failure.

  • Feasible administration with negligible toxicity.
  • Encouraging efficacy as a localized immune checkpoint inhibitor.
  • Intravesical delivery may surpass systemic approaches.”

“Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group”

Authors: Charalampos Fragkoulis, Aristotelis Bamias, Nikos Gavalas, Andreas Skolarikos, Athanasios Papatsoris et al.

Enrique Grande: Intravesical durvalumab shows promise for high-risk NMIBC after BCG failure

More posts featuring Enrique Grande.

Andreas Skolarikos Aristotelis Bamias Athanasios Papatsoris bladder cancer cancer Charalampos Fragkoulis Durvalumab Enrique Grande Hellenic GU Cancer Group Nikos Gavalas NMIBC Non-muscle-invasive Bladder Cancer OncoDaily Oncology